Continued advances within genomics and the application of genomic technologies, has resulted in developments in diagnosis, treatment and care management, as well as broadened the cope for research to enable an enhanced understanding and cancer care for patients.

As healthcare professionals working within cancer care it's vital that there is an understanding of the impact of genomics so that patients are informed, and involved in treatment decisions in relation to their ongoing care needs.

The Alliance has recently been involved in the national lung cancer and Lynch Syndrome genetic testing pathway projects.

Signposting to other available resources is shown below.

Genomic Bitesize_From Biopsy to personalised cancer care .png

Informed by two recent genomic transformation projects, we are collaborating with stakeholders across the North West, to develop a series of webinars for professionals working across cancer care in the NHS.

All webinars in the series will be available to watch on demand on this page, so please bookmark for future reference.

The individual presentations will also be avaialble as separate 'bite size' modules. 

Colorectal Cancer Care Genomics Webinar

Genomic tests for cancer patients have increased around 5-fold in the last few years and genomics is now a key component of colorectal cancer management.

Following the successful implementation of the national Lynch syndrome project, we are all routinely using genomics for our patients. In addition, genomic test results affect decisions about the choice of treatments such as immunotherapy or targeted treatment and influences the dose of treatments such as 5 FU.

Genomic testing continues to increase rapidly and everyone involved in bowel cancer management needs to be aware of the pathway of testing and the implications of the test results; genomic testing takes place at the Genomics Laboratory Hubs. For the North West this is located in Manchester.

The first part of this webinar will be given by Grace Berry, project manager from the Cheshire and Mersey Cancer Alliance and will cover the pathway from receipt of the biopsy or resection specimen in the pathology laboratory to receipt of the genomic test result by the clinical team.

The second part will be given by Dr Mike Braun, oncologist based at the Christie hospital in Manchester and will cover the rationale for genomic testing

We will then finish with a discussion of some clinical scenarios where earlier genomic testing may be appropriate.

Thank you to Grace Berry, Dr Mike Braun, James Wingfield, Professor James Hill, and Dr Glenda Beaman for their support.


The Macmillan Genomics Toolkit is designed to guide healthcare professionals to multiple education resources, pathway guidelines, clinical documents, patient support information and case studies to demonstrate the ‘Gold Standard’ of care once genomics has been embedded into practice.

GatewayC provide accessible, innovative and tailored information and support resources.